Skip to Content

Odefsey vs Complera - What's the difference between them?

Medically reviewed by Drugs.com. Last updated on Apr 12, 2019.

Official Answer

by Drugs.com

Both drugs are fixed-dose NNRTI (non-nucleoside reverse transcriptase inhibitor) and NRTI (nucleoside reverse transcriptase inhibitor) agents. However, the newer TAF formulation found in Odefsey is known as a "prodrug" of tenofovir and is inactive when it is first taken. After it enters the body, it is changed to its active form in the HIV-infected cell much more efficiently than TDF, which results in much lower levels of drug in the blood, but higher levels within the cells where HIV-1 replicates. Therefore, TAF can be given at roughly one-tenth the dose of TDF. Due to smaller doses and lower levels of tenofovir in the blood, kidney toxicity and decreased bone mineral density may be less of a concern with TAF, as noted by laboratory values in studies.

Odefsey (generic name emtricitabine, rilpivirine and tenofovir alafenamide [TAF]) and Complera (generic name emtricitabine, rilpivirine and tenofovir disoproxil fumarate [TDF]) are antiviral drugs that prevent HIV (human immunodeficiency virus) cells from multiplying in the body. HIV causes acquired immunodeficiency syndrome (AIDS). 

 

Related Drug Information

Hide